Analytical Data
-
Gene name
MECOM
- Application
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13465
-
Expression Region
1-169aa
-
AA Sequence
MRSKGRARKL ATNNECVYGN YPEIPLEEMP DADGVASTPS LNIQEPCSPA TSSEAFTPKE GSPYKAPIYI PDDIPIPAEF ELRESNMPGA GLGIWTKRKI EVGEKFGPYV GEQRSNLKDP SYGWEVHLPR SRRVSVHSWL YLGKRSSDVG IAFSQADVYM PGLQCAFLS
-
Molecular Weight
138,1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MECOM, also known as the EVI1 gene, plays a significant role in regulating gene expression and has been implicated in various biological processes, including hematopoiesis and development. Its dysregulation is associated with several hematologic malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Research on the recombinant form of MECOM protein focuses on elucidating its structure, function, and potential as a therapeutic target. Understanding MECOM's molecular mechanisms and interactions with other proteins provides insights into its oncogenic properties and pathways involved in cancer progression. Moreover, the study of MECOM may lead to the development of novel diagnostic and prognostic biomarkers, as well as targeted therapies that could improve treatment outcomes for patients with MECOM-associated malignancies. This research is crucial for advancing our knowledge of cancer biology and for the development of new strategies to combat these complex diseases.
